Feline Immunodeficiency Virus gp95 antibody | SU1-30

100% Secure

Mouse anti Feline Immunodeficiency Virus gp95

Product Type
Monoclonal Antibody
Clone
SU1-30
Isotype
IgG1
Product Code Applications Pack Size List Price Quantity
MCA2552
Datasheet
F FN WB
MSDS
0.25 mg loader

Mouse anti Feline Immunodeficiency Virus gp95 antibody, clone SU1-30 recognizes the relatively conserved E60 peptide (amino acid sequence SSWKQRNRWEWRPDF) located within the V3 region of FIV (Feline Immunodeficiency Virus) envelope glycoprotein SU,gp95.

The primary receptor for FIV infection of cats has been identified as the T-cell activation antigen CD134 which, along with CXC chemokine receptor 4 (CXCR4), facilitates the infection of CD4+ primary target cells, resulting in a depletion in the CD4+ population. Studies have shown that the V3 loop of SU,gp95 is a major immunogenic domain, suggested to contain the main determinants for the binding of FIV SU,gp95 to CXCR4 (Sundstrom, M. et al. 2008).

Mouse anti Feline Immunodeficiency Virus gp95 antibody, clone SU1-30 has been shown to inhibit the sCD134-activated entry of both clade B and clade C FIV strains (de Parseval, A. et al. 2006).

Mouse anti Feline Immunodeficiency Virus gp95 antibody, clone SU1-30 does not recognise Feline Leukaemia Virus, Feline Herpes Virus type 1, Feline Coronavirus or Feline Calicivirus.

Removal of Sodium Azide is recommended prior to use in functional studies - The use of EQU003 is recommended for this purpose.

Product Details

Target Species
Viral
Product Form
Purified IgG - liquid
Preparation
Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.05%Sodium Azide (NaN3)
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml

Storage Information

Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee
18 months from date of despatch

More Information

Regulatory
For research purposes only

Applications of Feline Immunodeficiency Virus gp95 antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry
Functional Assays
Western Blotting
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul
Western Blotting
MCA2552 detects a band of approximately 95kDa under reducing conditions

Secondary Antibodies Available

Description Product Code Applications Pack Size List Price Quantity
Rabbit F(ab')2 anti Mouse IgG:RPE STAR12A F 1 ml loader
Rabbit F(ab')2 anti Mouse IgG:HRP (Human Adsorbed) STAR13B C E P RE WB 1 mg loader
Rabbit F(ab')2 anti Mouse IgG:FITC STAR9B F 1 mg loader

Application Based External Images

Functional Assays

Product Specific References

References for Feline Immunodeficiency Virus gp95 antibody

  1. DeParseval, A. et al. (2006) Sequential CD134-CXCR4 interactions in feline immunodeficiency virus (FIV): soluble CD134 activates FIV Env for CXCR4-dependent entry and reveals a cryptic neutralization epitope.
    J Virol. 80 (6): 3088-91.
  2. Sundstrom, M. et al. (2008) Mapping of the CXCR4 binding site within variable region 3 of the feline immunodeficiency virus surface glycoprotein.
    J Virol. 82 (18): 9134-42.
  3. Klonjkowski, B. et al. (2009) Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS.
    Vaccine. 27: 928-39.

Further Reading

  1. Willett, B.J. et al. (2006) Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus.
    J Virol. 80 (7): 3386-94.